Parameters of glycemic control and adherence to treatment in type 2 diabetes mellitus insulin-taking patients


DOI: https://dx.doi.org/10.18565/therapy.2018.5.66-73

A.R. Volkova, V.V. Kalugina, E.N. Ostroukhova, O.D.Dygun

1 The Department of intermediate level therapy with the course of endocrinology, cardiology and functional diagnostics with the clinic FSBEI of Higher Education «Acad. I.P. Pavlov First Saint Petersburg state medical university» of the Ministry of Healthcare of Russia, Saint Petersburg, Russia; 2 Cherepovetz center of diabetology of Budgetary Institution of Health Care «Cherepovetz municiipal hospital № 2», Cherepovetz, Russia
Aim of the research. To study the parameters of glycemic control, injection technique and adherence to treatment in patients with type 2 diabetes mellitus (DM2) receiving insulin therapy.
Material and methods. 177 patients with DM2 receiving insulin therapy were examined. Participants in the study were divided into 3 groups: a basic-bolus scheme of insulin therapy, basal insulin therapy, and therapy with mix insulins. The parameters of glycemic control, daily doses of insulin were analyzed depending on the mode of insulin therapy. Statistical data were processed in the Statistica program. Results. Basal-bolus regime of insulin administration was used in 52% of patients, basal insulin therapy - in 21.5%, therapy with mix insulins - in 26.5%. Only 39% of study-involved participants achieved the target value of glycated hemoglobin <7.0%. Participants in the group of basal-bolus insulin therapy received a daily dose of insulin 3 times bigger (69.71 units) comparatively to participants in the basal insulin therapy group (24.89 units) (p = 0.0001). The use of a baseline bolus insulin regime did not improve control of carbohydrate metabolism in patients with diabetes mellitus - therefore there were fixed no significant differences between groups in the mean level of glycated hemoglobin, fasting glycaemia and postprandial. Only 2.8% of participants in the study used the correct insulin injection technique.
Keywords: type 2 diabetes mellitus, basic-bolus scheme of insulin therapy, insulin injection technique
Read entire article

Literature

  • Дедов И.И., Калашникова М.Ф., Белоусов Д.Ю., Колбин А.С., Рафальский В.В., Чеберда А.Е., Кантемирова М.А., Закиев В.Д., Фадеев В.В. Анализ стоимости болезни сахарного диабета 2 типа в Российской Федерации: результаты российского многоцентрового наблюдательного фармакоэпидемиологического исследования ФОРСАЙТ-СД2. Сахарный диабет. 2017; 20(6): 403–19.
  • Официальный сайт IDF DIABETES ATLAS [интернет], Eighth edition 2017. Доступно по http://diabetesatlas.org/IDF_Diabetes_Atlas_8e_interactive_EN/.
  • Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104–12.
  • Hoerger T.J., Segel J.E., Gregg E.W., Saaddine J.B. Is Glycemic Control Improving in U.S. Adults. Diabetes Care. 2007;31(1):81–6.
  • Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 8-й выпуск. Сахарный диабет. 2017;20(Suppl. 1):1–21.
  • Дедов И.И., Калашникова М.Ф., Белоусов Д.Ю., Рафальский В.В., Калашников В.Ю., Колбин А.С., Языкова Д.Р., Иваненко Л.Р.. Фармакоэпидемиологические аспекты мониторинга здоровья пациентов с сахарным диабетом 2 типа: результаты российского наблюдательного многоцентрового эпидемиологического исследования ФОРСАЙТ-СД2. Сахарный диабет. 2016; 19(6): 448.
  • Mata-Cases M., Casajuana M., Franch-Nadal J., Casellas A., Castell C., Vinagre I., Mauricio D., Bolíbar B. Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain. Eur. J. Health Econ. 2016;17(8):1001–10.
  • Frid A.H., Kreugel G., Grassi G., Halimi S., Hicks D., Hirsch L.J., Smith M.J., Wellhoener R., Bode B.W., Hirsch I.B., Kalra S., Ji L., Strauss K.W. New Insulin Delivery Recommendations. Mayo Clin. Proc. 2016; 91(9): 1231–55.
  • Майоров А.Ю., Мельникова О.Г.. Национальные рекомендации для медицинских работников по технике инъекций при лечении сахарного диабета, 2012. С. 4–35.
  • Frid A.H., Kreugel G., Grassi G., Halimi S., Hicks D., Hirsch L.J., Smith M.J., Wellhoener R., Bode B.W., Hirsch I.B., Kalra S., Ji L., Strauss K.W. Worldwide Injection Technique Questionnaire Study: Injecting Complications and the Role of the Professional. Mayo Clin. Proc. 2016; 91(9): 1224–30.
  • Nelson P.T., Smith C.D., Abner E.A. et al. Human cerebral neuropathology of type 2 diabetes mellitus. Biochim. Biophys. Acta. 2008; 1792(5): 454–69.
  • Гацких И.В., Петрова М.М., Веселова О.Ф., Шалда Т.П., Наркевич А.Н., Брикман И.Н. Анализ когнитивного статуса у пациентов с сахарным диабетом 2 типа. Сахарный диабет. 2017; 20(6): 435–7.
  • Vijan S., Hayward R.A., Ronis D.L., Hofer T.P. Brief report the burden of diabetes therapy implications for the design of effective patient-centered treatment regimens. J. Gen. Int. Med. 2005; 20(5): 479–82.
  • Farsaei S., Radfar M., Heydari Z., Abbasi F., Qorbani M. Insulin adherence in patients with diabetes: risk factors for injection omission. Primary care diabetes. 2014; 8(4): 338–45.
  • Schernthaner G. et al. Внедрение последних результатов исследований по сердечно-сосудистой безопасности сахароснижающих препаратов в клиническую практику: рекомендации Экспертной группы по диабету для Центральной и Восточной Европы (Central and Eastern European Diabetes Expert Group, CEEDEG). Cardiovasc. Diabet. 2017; 16: 137.
  • Frid A.H., Kreugel G., Grassi G., Halimi S., Hicks D., Hirsch L.J., Smith M.J., Wellhoener R., Bode B.W., Hirsch I.B., Kalra S., Ji L., Strauss K.W. Worldwide Injection Technique Questionnaire Study: Population Parameters and Imjection Pract. Mayo Clin. Proc. 2016; 91(9): 1212–23.
  • Peyrot M., Barnett A.H., Meneghini L.F., Schumm-Draeger P.M. Factors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet. Obes. Metab. 2012; 14(12): 1081–7.
  • Katz J. Why Doctors Don’t Disclose Uncertainty. Hastings Cent. Rep. 1984; 14(1): 35.


    • About the Autors

    Anna R. Volkova, MD, professor of the Department of intermediate level therapy with the course of endocrinology, cardiology and functional diagnostics with FSBEI of Higher Education «Acad. I.P. Pavlov First Saint Petersburg state medical university» clinic of the Ministry of Healthcare of Russia. Tel.: +7(812)338-66-46. E-mail: volkovaa@mail.ru.
    Valentina V. Kalugina, head of the Cherepovetz center of diabetology of Budgetary Institution of Health Care «Cherepovetz municiipal hospital № 2». Tel.: +7(820)267-47-01.
    Elena N. Ostroukhova, PhD, associate professor of the Department of intermediate level therapy with the course of endocrinology, cardiology and functional diagnostics with FSBEI of Higher Education «Acad. I.P. Pavlov First Saint Petersburg state medical university» clinic of the Ministry of Healthcare of Russia. Тel.: +7(812)338-66-46.
    Olga D. Dygun, assistant professor of the Department of intermediate level therapy with the course of endocrinology, cardiology and functional diagnostics with FSBEI of Higher Education «Acad. I.P. Pavlov First Saint Petersburg state medical university» clinic of the Ministry of Healthcare of Russia.Тel.: +7(812)338-66-46.

    Back to Content

    Бионика Медиа